Innate Pharma SA
PAR:IPH

Watchlist Manager
Innate Pharma SA Logo
Innate Pharma SA
PAR:IPH
Watchlist
Price: 1.96 EUR 1.14% Market Closed
Market Cap: 180.6m EUR

Wall Street
Price Targets

IPH Price Targets Summary
Innate Pharma SA

Wall Street analysts forecast IPH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IPH is 5.27 EUR with a low forecast of 2.45 EUR and a high forecast of 8.82 EUR.

Lowest
Price Target
2.45 EUR
25% Upside
Average
Price Target
5.27 EUR
169% Upside
Highest
Price Target
8.82 EUR
350% Upside
Innate Pharma SA Competitors:
Price Targets
688428
InnoCare Pharma Ltd
20% Downside
NRIX
Nurix Therapeutics Inc
215% Upside
ORGO
Organogenesis Holdings Inc
88% Upside
STTK
Shattuck Labs Inc
144% Upside
PEB
Pacific Edge Ltd
21% Downside
AVTE
Aerovate Therapeutics Inc
11% Downside
251120
Bio-FD&C Co Ltd
28% Upside
PYC
PYC Therapeutics Ltd
185% Upside

Revenue
Forecast

Revenue Estimate
Innate Pharma SA

For the last 8 years the compound annual growth rate for Innate Pharma SA's revenue is -17%. The projected CAGR for the next 3 years is 79%.

-17%
Past Growth
79%
Estimated Growth
Estimates Accuracy
-24%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Innate Pharma SA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
24%
Average Beat

Net Income
Forecast

Net Income Estimate
Innate Pharma SA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
54%
Average Beat
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is IPH's stock price target?
Price Target
5.27 EUR

According to Wall Street analysts, the average 1-year price target for IPH is 5.27 EUR with a low forecast of 2.45 EUR and a high forecast of 8.82 EUR.

What is Innate Pharma SA's Revenue forecast?
Projected CAGR
79%

For the last 8 years the compound annual growth rate for Innate Pharma SA's revenue is -17%. The projected CAGR for the next 3 years is 79%.

Back to Top